Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Forensic Manufacturing Qiagen topic
No spam. Unsubscribe anytime.
State labs flag QIAGEN cartridge problems after spike in low/no-DNA results; vendor quality process under review
Summary
Houston and other Texas labs reported an uptick in low or no DNA recoveries from QIAGEN easy-platform cartridges. The commission heard presentations from Houston Forensic Science Center staff and others describing the investigation, vendor communications, and recommended QC and reporting changes.
Houston Forensic Science Center (HFSC) staff and other Texas laboratories briefed the commission on a manufacturing-quality issue affecting QIAGEN Easy-system cartridges that produced a higher-than-expected rate of low or no DNA recovery in some lots.
HFSC representatives described a cluster of unintuitive negative or low-yield results beginning in mid-2024 and a marked increase in failures in a specific lot group (identified in staff materials as "lot F" among several lots examined). HFSC reported that between November 2022 and May 2024 the unintuitive-negative rate was about 2.8 percent in their test population, but from June to August 2024 the rate rose to about 14 percent for samples HFSC sent for external processing. HFSC92s blind-quality-control program helped identify the issue.
HFSC staff said they performed broad retesting (including 340 samples across platforms, dilution series, and recovery tests) and worked with QIAGEN92s quality and manufacturing teams. QIAGEN92s description of its QC process was summarized: sampling 36 cartridges (12 beginning, 12 middle, 12 end) from a large batch for a high-DNA QC target (about 4 ng). QIAGEN indicated it later changed the filling process in October 2024 (the vendor92s change in how it prefills intermediate bags), and QIAGEN identified a set of cartridge lot numbers in an April customer notification as problem lots.
HFSC and other labs said the vendor92s QC sampling (36 cartridges per large batch) is small relative to an 83,000-cartridge batch and that a statistically based inspection of that scale would require a larger random sample (HFSC provided an example hypergeometric calculation showing roughly 235 cartridges would be needed to detect a 1% defective rate with 95% confidence for an 83,000-item lot). Commission participants raised the concern that QIAGEN92s QC used high-level DNA for its internal checks, which might not reveal dilution-sensitive failures later observed at low-input samples.
Commission staff and laboratories noted several practical implications: (1) cartridge-based systems are single-use consumables and harder for a lab to QC at the individual-cartridge level; (2) differing lot-number practices and vendor customer notifications complicate identifying impacted cases; and (3) some lots that seemed problematic in practice were not included in the vendor92s initial customer notification. HFSC said it paused certain outsourced testing while investigating and has worked to identify potentially affected cases.
The commission heard that QIAGEN has engaged via meetings with its global QA staff and legal and that the vendor has provided lot-identification lists and an incident investigation. HFSC and other labs suggested improvements the vendor could make: broaden QC sample strategy (include lower-level DNA in QC runs or larger randomly sampled inspections), improve customer notifications that explicitly list affected lot numbers, and consider additional on-cartridge internal controls or pass/fail metrics.
No vote was required on the discussion item. Commissioners and lab leaders agreed to continue working with QIAGEN on root-cause analysis, to coordinate case-level identification and retesting plans where appropriate, and to share status updates with the commission. HFSC and its partners will continue to pursue retesting and case-impact assessments and to work with the vendor and accrediting bodies to finalize remedial controls and reporting practices.
